$PSTX News
Last published 1y ago
- 1y agoIKNAPSTXIkena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged CompanyGlobeNewswireBOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA) ("Ikena") and Inmagene Biopharmaceuticals ("Inmagene") today announced the appointment of Kristin Yarema, Ph.D. as Chief
- 1y agoANABDSGNPSTXXERS+1Bright Peak Therapeutics Appoints John Schmid to its Board of DirectorsGlobeNewswireSAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer,
- 1y agoPSTXPoseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual MeetingPR NewswirePoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral...
- 1y agoBERYPLLPSTXRKDAKuehn Law Encourages PSTX, BERY, PLL, and RKDA Investors to Contact Law FirmGlobeNewswireNEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
- 1y agoPSTXPoseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.PR NewswirePoseida Therapeutics, Inc. (Nasdaq: PSTX) ("Poseida"), a clinical-stage allogeneic cell therapy and genetic medicines company advancing...
- 1y agoPSTXPoseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical PipelinePR NewswirePoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral...
- 2y agoPSTXPoseida Therapeutics to Present at Two Upcoming Investor ConferencesPR NewswirePoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral...
- 2y agoPSTXPoseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024PR NewswirePoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral...
- 2y agoPSTXPoseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024PR NewswirePoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral...
- 2y agoPSTXPoseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary AngioedemaPR NewswirePoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral...
- 2y agoPSTXPoseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with RochePR NewswirePoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral...
- 2y agoPSTXPoseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024PR NewswirePoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral...
- 2y agoPSTXPoseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma PatientsPR NewswirePoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral...
- 2y agoPSTXPoseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple MyelomaPR NewswirePoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral...
- 2y agoPSTXPoseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual MeetingPR NewswirePoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral...
- 2y agoPSTXPoseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple MyelomaPR NewswirePoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral...
- 2y agoPSTXPoseida Therapeutics to Present at Upcoming Investor ConferencesPR NewswirePoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral...
- 2y agoPSTXPoseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024PR NewswirePoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral...
- 2y agoPSTXPoseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy ForumPR NewswirePoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral...
- 2y agoPSTXPoseida Therapeutics Announces Virtual 2024 Annual Meeting of StockholdersPR NewswirePoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral...
- 2y agoPSTXPoseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024PR NewswirePoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral...
- 2y agoPSTXPoseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual MeetingPR NewswirePoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral...
- 2y agoPSTXAstellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in OncologyPR NewswireAstellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Poseida Therapeutics, Inc. (NASDAQ: PSTX, President and CEO:...
- 2y agoPSTXAstellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in OncologyPR NewswireAstellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Poseida Therapeutics, Inc. (NASDAQ: PSTX, President and CEO:...
- 2y agoPSTXPoseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual MeetingPR NewswirePoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell therapy and genetic medicines company advancing a new class of treatments for...
- 2y agoPSTXPoseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline FocusPR NewswirePoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell therapy and genetic medicines company advancing a new class of treatments for...
- 2y agoPSTXPoseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple MyelomaPR NewswirePoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...
- 2y agoPSTXPoseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)PR NewswirePoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...
- 2y agoPSTXPoseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical OfficerPR NewswirePoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...
- 2y agoPSTXPoseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferencePR NewswirePoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...
- 2y agoPSTXPoseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple MyelomaPR NewswirePoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...
- 2y agoPSTXPoseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023PR NewswirePoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...
- 2y agoPSTXPoseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)PR NewswirePoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...
- 2y agoPSTXPoseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key MilestonesPR NewswirePoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...
- 2y agoPSTXPoseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual MeetingPR NewswirePoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...
- 3y agoPSTXPoseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023PR NewswirePoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...
- 3y agoPSTXPoseida Therapeutics to Present at Two Upcoming Investor ConferencesPR NewswirePoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...
- 3y agoPSTXPoseida Therapeutics to Present at the 65th ASH Annual Meeting and ExpositionPR NewswirePoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...
- 3y agoPSTXPoseida Therapeutics Announces Leadership TransitionPR NewswireMark Gergen to assume role of Executive Chairman of the Board of Directors of Poseida; Kristin Yarema, Ph.D., currently President, Cell Therapy, to be appointed President and CEO SAN DIEGO, Oct. 9, 2023 /PRNewswire/ --
- 3y agoPSTXPoseida Therapeutics to Present at Two Upcoming Investor ConferencesPR NewswireSAN DIEGO, Sept. 5, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today
- 3y agoPSTXPoseida Therapeutics Provides Financial Results for the Second Quarter of 2023PR NewswireSAN DIEGO, Aug. 8, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today
- 3y agoPSTXPoseida Therapeutics Announces Strategic Investment by Astellas and Provides Business UpdatePR Newswire$50 million strategic investment validates Poseida's proprietary technology and cell therapy approach and supports strategic and operational plans Implementing enhancements to ongoing allogeneic programs based upon
- 3y agoALPMYPSTXTYO:4503Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell TherapyPR NewswirePoseida is a clinical-stage biotechnology company dedicated to advancing a new class of cancer cell therapy and gene therapy products using genetic engineering technologies Astellas to invest a total of $50 million to
- 3y agoPSTXPoseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-CD19CD20-ALLO1, an Allogeneic Dual CAR-T Cell Therapy for B-Cell MalignanciesPR NewswireBelieved to be the first FDA IND clearance of an allogeneic dual CAR-T therapy targeting CD19 and CD20 SAN DIEGO, July 5, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage cell and gene
- 3y agoPSTXPoseida Therapeutics to Join Russell 3000® and Russell 2000® IndexesPR NewswireSAN DIEGO, June 26, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today
- 3y agoPSTXPoseida Therapeutics Announces Virtual 2023 Annual Meeting of StockholdersPR NewswireSAN DIEGO, June 1, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today
- 3y agoPSTXPoseida Therapeutics to Present at Stifel 2023 Tailoring Genes: Genetic Medicines DayPR NewswireSAN DIEGO, May 23, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today
- 3y agoPSTXPoseida Therapeutics to Present at 31st Congress of the International Society on Thrombosis and HaemostasisPR NewswireSAN DIEGO, May 22, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today
- 3y agoPSTXPoseida Therapeutics Presents Encouraging Preclinical Data Across its Gene Therapy Programs at the American Society for Gene and Cell Therapy 2023 Annual MeetingPR NewswireSix presentations highlight significant advancements across the Company's Gene Therapy platform Preclinical data supports potential of P-OTC-101 to correct severe Ornithine Transcarbamylase Deficiency (OTCD)
- 3y agoPSTXPoseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2023PR NewswireHighlighted significant research, preclinical advances and platform technology progress at third annual R&D Day Appointed Kristin Yarema, Ph.D., as President, Cell Therapy, adding extensive oncology and allogeneic T